{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:36:04Z","timestamp":1762673764095,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T00:00:00Z","timestamp":1269648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmied Arch Pharmacol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00210-010-0505-x","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T09:19:19Z","timestamp":1269595159000},"page":"495-505","source":"Crossref","is-referenced-by-count":24,"title":["NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities"],"prefix":"10.1007","volume":"381","author":[{"given":"Heng-Lan","family":"Kuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Cherng","family":"Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyh-Chyi","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Chun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Chu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tur-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,27]]},"reference":[{"key":"505_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1592\/phco.29.2.167","volume":"29","author":"PJ Abrams","year":"2009","unstructured":"Abrams PJ, Emerson CR (2009) Rivaroxaban: a novel, oral, direct factor Xa inhibitor. Pharmacotherapy 29:167\u2013181","journal-title":"Pharmacotherapy"},{"key":"505_CR2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1046\/j.1538-7836.2003.00245.x","volume":"1","author":"BT Atkinson","year":"2003","unstructured":"Atkinson BT, Jarvis GE, Watson SP (2003) Activation of GPVI by collagen is regulated by alpha2beta1 and secondary mediators. J Thromb Haemost 1:1278\u20131287","journal-title":"J Thromb Haemost"},{"key":"505_CR3","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1592\/phco.28.11.1354","volume":"28","author":"BE Baetz","year":"2008","unstructured":"Baetz BE, Spinler SA (2008) Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28:1354\u20131373","journal-title":"Pharmacotherapy"},{"key":"505_CR4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1113\/jphysiol.1963.sp007185","volume":"168","author":"GV Born","year":"1963","unstructured":"Born GV, Cross MJ (1963) The aggregation of blood platelets. J Physiol 168:178\u2013195","journal-title":"J Physiol"},{"key":"505_CR5","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.V91.5.1582","volume":"91","author":"MC Chang","year":"1998","unstructured":"Chang MC, Lin HK, Peng HC, Huang TF (1998) Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox. Blood 91:1582\u20131589","journal-title":"Blood"},{"key":"505_CR6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.CIR.102.9.1007","volume":"102","author":"F Cipollone","year":"2000","unstructured":"Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G, Cuccurullo F, Patrono C (2000) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102:1007\u20131013","journal-title":"Circulation"},{"key":"505_CR7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0065-2776(08)60837-8","volume":"33","author":"CG Cochrane","year":"1982","unstructured":"Cochrane CG, Griffin JH (1982) The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 33:241\u2013306","journal-title":"Adv Immunol"},{"key":"505_CR8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1476-5381.1981.tb16814.x","volume":"73","author":"RA Coleman","year":"1981","unstructured":"Coleman RA, Humphrey PP, Kennedy I, Levy GP, Lumley P (1981) Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol 73:773\u2013778","journal-title":"Br J Pharmacol"},{"key":"505_CR9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1084\/jem.20060217","volume":"203","author":"RW Colman","year":"2006","unstructured":"Colman RW (2006) Are hemostasis and thrombosis two sides of the same coin? J Exp Med 203:493\u2013495","journal-title":"J Exp Med"},{"key":"505_CR10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2174\/1381612043384673","volume":"10","author":"D Cox","year":"2004","unstructured":"Cox D (2004) Oral GPIIb\/IIIa antagonists: what went wrong? Curr Pharm Des 10:1587\u20131596","journal-title":"Curr Pharm Des"},{"key":"505_CR11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0038-1657230","volume":"48","author":"E Dejana","year":"1982","unstructured":"Dejana E, Villa S, de Gaetano G (1982) Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost 48:108\u2013111","journal-title":"Thromb Haemost"},{"key":"505_CR12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/jpet.103.063610","volume":"309","author":"JM Dogne","year":"2004","unstructured":"Dogne JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, Masereel B, Pirotte B (2004a) Pharmacological characterization of N-tert-butyl-N\u2032-[2-(4\u2032-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J Pharmacol Exp Ther 309:498\u2013505","journal-title":"J Pharmacol Exp Ther"},{"key":"505_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/1389557043403684","volume":"4","author":"JM Dogne","year":"2004","unstructured":"Dogne JM, Hanson J, de Leval X, Masereel B, Kolh P, Pirotte B (2004b) New developments on thromboxane modulators. Mini Rev Med Chem 4:649\u2013657","journal-title":"Mini Rev Med Chem"},{"key":"505_CR14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ejim.2009.09.005","volume":"20","author":"M Franchini","year":"2009","unstructured":"Franchini M, Mannucci PM (2009) New antiplatelet agents: why they are needed. Eur J Intern Med 20:733\u2013738","journal-title":"Eur J Intern Med"},{"key":"505_CR15","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1161\/CIRCULATIONAHA.104.494468","volume":"112","author":"JE Freedman","year":"2005","unstructured":"Freedman JE (2005) Molecular regulation of platelet-dependent thrombosis. Circulation 112:2725\u20132734","journal-title":"Circulation"},{"key":"505_CR16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0090-6980(83)90099-0","volume":"26","author":"RR Gorman","year":"1983","unstructured":"Gorman RR, Johnson RA, Spilman CH, Aiken JW (1983) Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3\u2032-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins 26:325\u2013342","journal-title":"Prostaglandins"},{"key":"505_CR17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00228-001-0392-7","volume":"57","author":"J Hauptmann","year":"2002","unstructured":"Hauptmann J (2002) Pharmacokinetics of an emerging new class of anticoagulant\/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 57:751\u2013758","journal-title":"Eur J Clin Pharmacol"},{"key":"505_CR18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0037-1613209","volume":"88","author":"JW Heemskerk","year":"2002","unstructured":"Heemskerk JW, Bevers EM, Lindhout T (2002) Platelet activation and blood coagulation. Thromb Haemost 88:186\u2013193","journal-title":"Thromb Haemost"},{"key":"505_CR19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd1198","volume":"2","author":"SP Jackson","year":"2003","unstructured":"Jackson SP, Schoenwaelder SM (2003) Antiplatelet therapy: in search of the \u2018magic bullet\u2019. Nat Rev Drug Discov 2:775\u2013789","journal-title":"Nat Rev Drug Discov"},{"key":"505_CR20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20052458","volume":"203","author":"C Kleinschnitz","year":"2006","unstructured":"Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T (2006) Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203:513\u2013518","journal-title":"J Exp Med"},{"key":"505_CR21","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1067\/mhj.2002.121806","volume":"143","author":"D Langleben","year":"2002","unstructured":"Langleben D, Christman BW, Barst RJ, Dias VC, Galie N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Soler M (2002) Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 143:E4","journal-title":"Am Heart J"},{"key":"505_CR22","doi-asserted-by":"crossref","first-page":"108S","DOI":"10.1378\/chest.119.1_suppl.108S","volume":"119","author":"MN Levine","year":"2001","unstructured":"Levine MN, Raskob G, Landefeld S, Kearon C (2001) Hemorrhagic complications of anticoagulant treatment. Chest 119:108S\u2013121S","journal-title":"Chest"},{"key":"505_CR23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354\u2013362","journal-title":"N Engl J Med"},{"key":"505_CR24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2141.1972.tb08800.x","volume":"22","author":"JF Mustard","year":"1972","unstructured":"Mustard JF, Perry DW, Ardlie NG, Packham MA (1972) Preparation of suspensions of washed platelets from humans. Br J Haematol 22:193\u2013204","journal-title":"Br J Haematol"},{"key":"505_CR25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1021\/jm00061a008","volume":"36","author":"E Nicolai","year":"1993","unstructured":"Nicolai E, Goyard J, Benchetrit T, Teulon JM, Caussade F, Virone A, Delchambre C, Cloarec A (1993) Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists. J Med Chem 36:1175\u20131187","journal-title":"J Med Chem"},{"key":"505_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1650118","volume":"45","author":"B Nunn","year":"1981","unstructured":"Nunn B (1981) Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro. Thromb Haemost 45:1\u20135","journal-title":"Thromb Haemost"},{"key":"505_CR27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0022-3565(25)21554-3","volume":"228","author":"LV Parise","year":"1984","unstructured":"Parise LV, Venton DL, Le Breton GC (1984) Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2\/prostaglandin H2 receptor interaction. J Pharmacol Exp Ther 228:240\u2013244","journal-title":"J Pharmacol Exp Ther"},{"key":"505_CR28","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1046\/j.1538-7836.2003.00284.x","volume":"1","author":"C Patrono","year":"2003","unstructured":"Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1:1710\u20131713","journal-title":"J Thromb Haemost"},{"key":"505_CR29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-0037-1617033","volume":"29","author":"E Perzborn","year":"2009","unstructured":"Perzborn E (2009) Factor Xa inhibitors\u2014new anticoagulants for secondary haemostasis. Hamostaseologie 29:260\u2013267","journal-title":"Hamostaseologie"},{"key":"505_CR30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","volume":"202","author":"T Renne","year":"2005","unstructured":"Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B (2005) Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202:271\u2013281","journal-title":"J Exp Med"},{"key":"505_CR31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bcmd.2005.12.014","volume":"36","author":"T Renne","year":"2006","unstructured":"Renne T, Nieswandt B, Gailani D (2006) The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis 36:148\u2013151","journal-title":"Blood Cells Mol Dis"},{"key":"505_CR32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.plefa.2003.12.004","volume":"71","author":"DJ Son","year":"2004","unstructured":"Son DJ, Cho MR, Jin YR, Kim SY, Park YH, Lee SH, Akiba S, Sato T, Yun YP (2004) Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids 71:25\u201331","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"505_CR33","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1021\/bi00074a003","volume":"32","author":"IP Street","year":"1993","unstructured":"Street IP, Lin HK, Laliberte F, Ghomashchi F, Wang Z, Perrier H, Tremblay NM, Huang Z, Weech PK, Gelb MH (1993) Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry 32:5935\u20135940","journal-title":"Biochemistry"},{"key":"505_CR34","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/j.1538-7836.2005.01372.x","volume":"3","author":"A Szczeklik","year":"2005","unstructured":"Szczeklik A, Musial J, Undas A, Sanak M (2005) Aspirin resistance. J Thromb Haemost 3:1655\u20131662","journal-title":"J Thromb Haemost"},{"key":"505_CR35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-2999(98)00540-8","volume":"357","author":"T Tanaka","year":"1998","unstructured":"Tanaka T, Fukuta Y, Higashino R, Sato R, Nomura Y, Fukuda Y, Ito S, Takei M, Kurimoto T, Tamaki H (1998) Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist. Eur J Pharmacol 357:53\u201360","journal-title":"Eur J Pharmacol"},{"key":"505_CR36","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1517\/14656566.6.12.2027","volume":"6","author":"US Tantry","year":"2005","unstructured":"Tantry US, Bliden KP, Gurbel PA (2005) Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 6:2027\u20132045","journal-title":"Expert Opin Pharmacother"},{"key":"505_CR37","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1172\/JCI5116","volume":"102","author":"DW Thomas","year":"1998","unstructured":"Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH, Coffman TM (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 102:1994\u20132001","journal-title":"J Clin Invest"},{"key":"505_CR38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/01.CIR.99.5.682","volume":"99","author":"JI Weitz","year":"1999","unstructured":"Weitz JI, Young E, Johnston M, Stafford AR, Fredenburgh JC, Hirsh J (1999) Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation 99:682\u2013689","journal-title":"Circulation"},{"key":"505_CR39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.atherosclerosis.2005.02.034","volume":"183","author":"NF Worth","year":"2005","unstructured":"Worth NF, Berry CL, Thomas AC, Campbell JH (2005) S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 183:65\u201373","journal-title":"Atherosclerosis"},{"key":"505_CR40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2003-10-3661","volume":"104","author":"IS Yu","year":"2004","unstructured":"Yu IS, Lin SR, Huang CC, Tseng HY, Huang PH, Shi GY, Wu HL, Tang CL, Chu PH, Wang LH, Wu KK, Lin SW (2004) TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood 104:135\u2013142","journal-title":"Blood"},{"key":"505_CR41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH09-06-0378","volume":"103","author":"MU Zafar","year":"2010","unstructured":"Zafar MU, Ibanez B, Choi BG, Vorchheimer DA, Pinero A, Jin X, Sharma RK, Badimon JJ (2010) A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel in a randomised phase I study. Thromb Haemost 103:205\u2013212","journal-title":"Thromb Haemost"},{"key":"505_CR42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0960-894X(00)00139-6","volume":"10","author":"Z Zhao","year":"2000","unstructured":"Zhao Z, Arnaiz DO, Griedel B, Sakata S, Dallas JL, Whitlow M, Trinh L, Post J, Liang A, Morrissey MM, Shaw KJ (2000) Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors. Bioorg Med Chem Lett 10:963\u2013966","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-010-0505-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-010-0505-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-010-0505-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T18:28:41Z","timestamp":1739989721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-010-0505-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,27]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["505"],"URL":"https:\/\/doi.org\/10.1007\/s00210-010-0505-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"type":"print","value":"0028-1298"},{"type":"electronic","value":"1432-1912"}],"subject":[],"published":{"date-parts":[[2010,3,27]]}}}